{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:15:34Z","timestamp":1785726934686,"version":"3.56.0"},"reference-count":46,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Background: Clinical experience with semaglutide in patients with type 2 diabetes mellitus shows that its benefits extend far beyond glucose regulation. This study examines whether this drug is indeed popular among the Croatian population and explores whether factors such as gender or proximity to the healthcare sector influence its potential use, attitudes toward weight loss, and knowledge regarding its application and possible adverse effects. Methods: This was a cross-sectional population study. In this study we focused on the brand name Ozempic\u00ae for semaglutide as it is the most commonly searched term for semaglutide. Results: The study included 290 participants, most of who were women (N = 243, 83.8%). As many as 214 (73.8%) people stated they had heard of Ozempic\u00ae; however, there was no significant difference in whether people had heard of Ozempic\u00ae if they had type 2 diabetes mellitus (p = 0.415). In total, 23.4% of people stated they knew someone who took Ozempic\u00ae. Women were significantly more likely to feel pressure about their appearance than men, with 51.1% of men reporting no pressure at all compared to only 39.9% of women (p = 0.015). A majority of participants agreed that social media strongly affects perception on the use of medications for weight loss (73.8%). Individuals with a family member in the healthcare field were significantly more informed about the possible adverse reactions of semaglutide compared to those without such a connection. Among participants without a healthcare professional in the family, 75.0% reported being unaware of potential adverse effects, compared to 47.9% of those with a family member in healthcare. Moreover, participants with a healthcare professional in the family were more likely to know the correct route of administration for Ozempic\u00ae (68.1% vs. 54.6%, p = 0.025); Conclusions: The results of this study show that three-quarters of people had heard of Ozempic\u00ae, regardless of whether they had an indication for its use or not. In addition, the results indicate that although both men and women share satisfaction with their bodies, women feel more pressured by societal expectations related to their appearance.<\/jats:p>","DOI":"10.3390\/pharmacy13050128","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:31:21Z","timestamp":1756999881000},"page":"128","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Semaglutide in the Real World: Attitudes of the Population"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7018-4947","authenticated-orcid":false,"given":"Doris","family":"Ru\u0161i\u0107","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Split School of Medicine, \u0160oltanska 2A, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8489-3617","authenticated-orcid":false,"given":"Toni","family":"Durdov","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Split School of Medicine, \u0160oltanska 2A, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivona","family":"Jadrijevi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Split School of Medicine, \u0160oltanska 2A, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7927-5311","authenticated-orcid":false,"given":"Ana","family":"\u0160e\u0161elja Peri\u0161in","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Split School of Medicine, \u0160oltanska 2A, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5126-3869","authenticated-orcid":false,"given":"Dario","family":"Leskur","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Split School of Medicine, \u0160oltanska 2A, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1634-0635","authenticated-orcid":false,"given":"Jo\u0161ko","family":"Bo\u017ei\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, University of Split School of Medicine, \u0160oltanska 2A, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila Marie","family":"Klusmeier","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Split School of Medicine, \u0160oltanska 2A, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9316-5538","authenticated-orcid":false,"given":"Josipa","family":"Buki\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Split School of Medicine, \u0160oltanska 2A, 21000 Split, Croatia"},{"name":"Department of Laboratory Medicine and Pharmacy, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Josipa Huttlera 4, 31000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"v247","DOI":"10.1093\/eurheartjsupp\/suaf071","article-title":"ANMCO statement: Semaglutide in the cardio-nephro-metabolic continuum","volume":"27","author":"Bilato","year":"2025","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_2","first-page":"251","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The lancet","volume":"5","author":"Sorli","year":"2017","journal-title":"Diabetes Endocrinol."},{"key":"ref_3","first-page":"563","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): A double-blind, randomised, phase 3B trial. The lancet","volume":"9","author":"Auerbach","year":"2021","journal-title":"Diabetes Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12793\/tcp.2025.33.e3","article-title":"Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: Focusing on early phase clinical trials","volume":"33","author":"Won","year":"2025","journal-title":"Transl. Clin. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/00325481.2022.2147326","article-title":"Efficacy and safety of semaglutide for weight management: Evidence from the STEP program","volume":"134","author":"Amaro","year":"2022","journal-title":"Postgrad. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2231982","DOI":"10.1001\/jamanetworkopen.2022.31982","article-title":"Weight Loss Outcomes Associated with Semaglutide Treatment for Patients with Overweight or Obesity","volume":"5","author":"Ghusn","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.15605\/jafes.037.02.14","article-title":"Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis","volume":"37","author":"Tan","year":"2022","journal-title":"J. ASEAN Fed. Endocr. Soc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e65440","DOI":"10.2196\/65440","article-title":"Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study","volume":"26","author":"Ashraf","year":"2024","journal-title":"J. Med. Internet Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ryan, N., and Savulescu, J. (2025). The Ethics of Ozempic and Wegovy. J. Med. Ethics, jme-2024-110374.","DOI":"10.1136\/jme-2024-110374"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Raubenheimer, J.E., Myburgh, P.H., and Bhagavathula, A.S. (2024). Sweetening the deal: An infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface. BMC Glob. Public Health, 2.","DOI":"10.1186\/s44263-024-00095-w"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101910","DOI":"10.4254\/wjh.v17.i4.101910","article-title":"Is global interest in fasting, intermittent fasting and the liver shifting?","volume":"17","author":"Tselebis","year":"2025","journal-title":"World J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e70094","DOI":"10.1111\/jocd.70094","article-title":"Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study","volume":"24","author":"Nikolis","year":"2025","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"20420986251332737","DOI":"10.1177\/20420986251332737","article-title":"Semaglutide: A gendered phenomenon-women\u2019s increased vulnerability to adverse drug reactions in the global weight loss trend","volume":"16","author":"Castellana","year":"2025","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Reitzinger, S., and Czypionka, T. (2025). Effects from treating moderate- to high-risk obesity patients with anti-obesity medication from a societal perspective. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-97472-8"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/13696998.2025.2459529","article-title":"Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes","volume":"28","author":"McEwan","year":"2025","journal-title":"J. Med. Econ."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e245586","DOI":"10.1001\/jamahealthforum.2024.5586","article-title":"Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults","volume":"6","author":"Hwang","year":"2025","journal-title":"JAMA Health Forum"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e252008","DOI":"10.1001\/jamanetworkopen.2025.2008","article-title":"Older Adults\u2019 Views on Insurance Coverage for Weight Management Medications","volume":"8","author":"Oshman","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e70080","DOI":"10.1002\/prp2.70080","article-title":"Analysis of Reporting Trends of Serious Adverse Events Associated With Anti-Obesity Drugs","volume":"13","year":"2025","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_25","first-page":"e71569","article-title":"Population-Level Interest in Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Using Google Trends Statistics in a 12-Month Retrospective Analysis: An Infodemiology and Infoveillance Study","volume":"16","author":"Shareef","year":"2024","journal-title":"Cureus"},{"key":"ref_26","unstructured":"(2025, May 21). Agency for Medicinal Products and Medical Devices. Medicinal Products Database. Ozempic Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/hr\/documents\/product-information\/ozempic-epar-product-information_hr.pdf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jadohealth.2025.02.011","article-title":"Youth Perspectives on the Use of Medications for Weight Loss","volume":"77","author":"Peyyety","year":"2025","journal-title":"J. Adolesc. Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/dom.16222","article-title":"Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects","volume":"27","author":"Sorensen","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e70063","DOI":"10.1111\/1753-0407.70063","article-title":"Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis","volume":"17","author":"Yang","year":"2025","journal-title":"J. Diabetes"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"117646","DOI":"10.1016\/j.socscimed.2024.117646","article-title":"Quality of information and social norms in Spanish-speaking TikTok videos as levers of commercial practices: The case of semaglutide","volume":"366","author":"Wirtz","year":"2025","journal-title":"Soc. Sci. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e24336","DOI":"10.2196\/24336","article-title":"Areas of Interest and Attitudes Toward Antiobesity Drugs: Thematic and Quantitative Analysis Using Twitter","volume":"23","author":"Ortega","year":"2021","journal-title":"J. Med. Internet Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/87551225251332212","article-title":"Changes in Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Exposures Following Recent Demand for Weight Management: A Retrospective Review of California Poison Control System Data","volume":"41","author":"Ho","year":"2025","journal-title":"J. Pharm. Technol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries","volume":"277","author":"Lakhani","year":"2025","journal-title":"Am. J. Ophthalmol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zhao, T., Zheng, L., Feng, Y., Lao, M., Huang, Y., and Wu, G. (2025). Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting. BMC Ophthalmol., 25.","DOI":"10.1186\/s12886-025-04096-7"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Massy, M., Marti, S., Hammer, H., and Hoepner, R. (2025). Increased vision impairment reports linked to semaglutide: Analysis of FDA adverse event data. BMC Med., 23.","DOI":"10.1186\/s12916-025-04031-z"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e70085","DOI":"10.1111\/1753-0407.70085","article-title":"Semaglutide and the Retina","volume":"17","author":"Bloomgarden","year":"2025","journal-title":"J. Diabetes"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1192\/j.eurpsy.2024.1803","article-title":"Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: A pharmacovigilance analysis of the FDA Adverse Event Reporting System database","volume":"68","author":"Lu","year":"2025","journal-title":"Eur. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e59767","DOI":"10.2196\/59767","article-title":"Online Information About Side Effects and Safety Concerns of Semaglutide: Mixed Methods Study of YouTube Videos","volume":"5","author":"Yeung","year":"2025","journal-title":"JMIR Infodemiology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1744133124000306","article-title":"The prevalence and consequences of support for off-label Ozempic prescriptions","volume":"7","author":"Callaghan","year":"2025","journal-title":"Health Econ. Policy Law"},{"key":"ref_41","first-page":"664","article-title":"Subcutaneous Semaglutide Use for Weight Management: Practice and Attitudes of Physicians in Israel","volume":"25","author":"Dicker","year":"2023","journal-title":"Isr. Med. Assoc. J. IMAJ"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"iii98","DOI":"10.1093\/eurheartjsupp\/suaf024","article-title":"From the SELECT study to SOUL: Different administration methods of semaglutide but same efficacy?","volume":"27","author":"Gatto","year":"2025","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_43","first-page":"e82497","article-title":"Comparative Effectiveness and Safety of Oral Versus Subcutaneous Semaglutide in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","volume":"17","author":"Karedath","year":"2025","journal-title":"Cureus"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Abutaima, R., Barakat, M., Sawan, H.M., Al Omari, S.M., and Mhaidat, N.M. (2024). Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0314407"},{"key":"ref_45","first-page":"e42875","article-title":"Knowledge and Attitude of the General Population in Saudi Arabia Toward Weight Management Medications (WMMs): A Cross-Sectional Study","volume":"15","author":"Algarni","year":"2023","journal-title":"Cureus"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1002\/osp4.783","article-title":"Patient perspectives on incretin-based weight loss medications and relationship with demographic factors","volume":"10","author":"McVay","year":"2024","journal-title":"Obes. Sci. Pract."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/5\/128\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:39:45Z","timestamp":1760035185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/5\/128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["pharmacy13050128"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy13050128","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}